Detalhe da pesquisa
1.
Ceritinib in ALK-rearranged non-small-cell lung cancer.
N Engl J Med
; 370(13): 1189-97, 2014 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24670165
2.
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.
Proc Natl Acad Sci U S A
; 110(50): 20224-9, 2013 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24277854
3.
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms.
Orphanet J Rare Dis
; 18(1): 69, 2023 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36964624
4.
Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.
Blood
; 126(10): 1257-8, 2015 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26337354
5.
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study.
Orphanet J Rare Dis
; 16(1): 434, 2021 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34663404
6.
Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©.
Orphanet J Rare Dis
; 16(1): 414, 2021 10 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34627355
7.
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).
Leuk Res
; 108: 106606, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34004551
8.
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Br J Haematol
; 144(6): 895-903, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19170677
9.
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Br J Haematol
; 143(1): 46-53, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18673366
10.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
N Engl J Med
; 352(24): 2487-98, 2005 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-15958804
11.
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Clin Lymphoma Myeloma
; 7(3): 233-5, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17229340
12.
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.
Leuk Lymphoma
; 51(7): 1269-77, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20572799
13.
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
J Thorac Oncol
; 4(9): 1156-62, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19704336
14.
Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
J Clin Oncol
; 27(30): 5023-30, 2009 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19770386
15.
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
J Clin Oncol
; 24(30): 4867-74, 2006 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-17001068